Celgene Fined $280 Million

LOS ANGELES — Celgene will pay $280 million to the United States, 28 states and the District of Columbia to settle claims it promoted cancer drugs Thalomid and Revlimid for unapproved uses and submitted fraudulent Medicare and Medi-Cal claims for it, federal prosecutors said Tuesday.

%d bloggers like this: